Dr Reddy’s Laboratories to challenge patents on drugs

by Medindia Content Team on  January 10, 2002 at 11:07 AM Drug News
RSS Email Print This Page Comment
Font : A-A+

Dr Reddy’s Laboratories to challenge patents on drugs
Pharma major Dr Reddy's Laboratories will continue to aggressively challenge patents on drugs in the US despite the recent denial of a 180-day marketing exclusivity to its generic Omeprazole 40 mg capsules by the US Food and Drug Administration. Omeprazole is indicated for the treatment of duodenal and gastric ulcers.

The FDA granted the marketing exclusivity to Andrx group of the US. The loss of marketing exclusivity is a setback for Dr Reddy's, but this will be temporary. This is to be expected in the game of patent challenges but since generic drugs provide an enormous opportunity, Dr Reddy's Laboratories will continue to aggressively challenge the patents on other drugs.

Apart from generic drug challenges, Dr Reddy's Laboratories is also focusing on patent generic drugs, innovative drug deliveries and drugs which are difficult to formulate. Nothing can be as profitable as a generic drug, because of the manufacturing cost advantage. In fact, the marketing exclusivity on fluoxetine is the best thing to have happened to Dr Reddy's in a very long time.

The next generic drug which Dr Reddy's hopes to launch in the US is Ciprofloxacin, on which Bayer AG has a patent till December 2003. Other generic drugs in Dr Reddy's pipeline are Olanzapine, on which Eli Lilly has a patent, and Ondansetron, on which Glaxo SmithKline Beecham has the patent, but these will be in 2004.

Post a Comment

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
Notify me when reply is posted
I agree to the terms and conditions

More News on:

Drug Toxicity Signature Drug Toxicity 

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Stay Connected

  • Available on the Android Market
  • Available on the App Store

Facebook

News Category

News Archive